Nicole A P Lieberman1, Kole DeGolier1, Heather M Kovar1, Amira Davis1, Virginia Hoglund1, Jeffrey Stevens2, Conrad Winter3, Gail Deutsch4, Scott N Furlan1, Nicholas A Vitanza5, Sarah E S Leary5, Courtney A Crane1,6. 1. Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington. 2. Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington. 3. Seattle Children's Hospital Pathology, Seattle, Washington. 4. Department of Pathology, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington. 5. Division of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington. 6. Department of Neurological Surgery, University of Washington, Seattle, Washington.
Abstract
Background: Diffuse intrinsic pontine glioma (DIPG) is a uniformly fatal CNS tumor diagnosed in 300 American children per year. Radiation is the only effective treatment and extends overall survival to a median of 11 months. Due to its location in the brainstem, DIPG cannot be surgically resected. Immunotherapy has the ability to target tumor cells specifically; however, little is known about the tumor microenvironment in DIPGs. We sought to characterize infiltrating immune cells and immunosuppressive factor expression in pediatric low- and high-grade gliomas and DIPG. Methods: Tumor microarrays were stained for infiltrating immune cells. RNA was isolated from snap-frozen tumor tissue and Nanostring analysis performed. DIPG and glioblastoma cells were co-cultured with healthy donor macrophages, T cells, or natural killer (NK) cells, and flow cytometry and cytotoxicity assays performed to characterize the phenotype and function, respectively, of the immune cells. Results: DIPG tumors do not have increased macrophage or T-cell infiltration relative to nontumor control, nor do they overexpress immunosuppressive factors such as programmed death ligand 1 and/or transforming growth factor β1. H3.3-K27M DIPG cells do not repolarize macrophages, but are not effectively targeted by activated allogeneic T cells. NK cells lysed all DIPG cultures. Conclusions: DIPG tumors have neither a highly immunosuppressive nor inflammatory microenvironment. Therefore, major considerations for the development of immunotherapy will be the recruitment, activation, and retention of tumor-specific effector immune cells.
Background: Diffuse intrinsic pontine glioma (DIPG) is a uniformly fatal CNS tumor diagnosed in 300 American children per year. Radiation is the only effective treatment and extends overall survival to a median of 11 months. Due to its location in the brainstem, DIPG cannot be surgically resected. Immunotherapy has the ability to target tumor cells specifically; however, little is known about the tumor microenvironment in DIPGs. We sought to characterize infiltrating immune cells and immunosuppressive factor expression in pediatric low- and high-grade gliomas and DIPG. Methods:Tumor microarrays were stained for infiltrating immune cells. RNA was isolated from snap-frozen tumor tissue and Nanostring analysis performed. DIPG and glioblastoma cells were co-cultured with healthy donor macrophages, T cells, or natural killer (NK) cells, and flow cytometry and cytotoxicity assays performed to characterize the phenotype and function, respectively, of the immune cells. Results:DIPG tumors do not have increased macrophage or T-cell infiltration relative to nontumor control, nor do they overexpress immunosuppressive factors such as programmed death ligand 1 and/or transforming growth factor β1. H3.3-K27MDIPG cells do not repolarize macrophages, but are not effectively targeted by activated allogeneic T cells. NK cells lysed all DIPG cultures. Conclusions: DIPG tumors have neither a highly immunosuppressive nor inflammatory microenvironment. Therefore, major considerations for the development of immunotherapy will be the recruitment, activation, and retention of tumor-specific effector immune cells.
Authors: Michelle Monje; Siddhartha S Mitra; Morgan E Freret; Tal B Raveh; James Kim; Marilyn Masek; Joanne L Attema; Gordon Li; Terri Haddix; Michael S B Edwards; Paul G Fisher; Irving L Weissman; David H Rowitch; Hannes Vogel; Albert J Wong; Philip A Beachy Journal: Proc Natl Acad Sci U S A Date: 2011-03-01 Impact factor: 11.205
Authors: Andrea M Griesinger; Diane K Birks; Andrew M Donson; Vladimir Amani; Lindsey M Hoffman; Allen Waziri; Michael Wang; Michael H Handler; Nicholas K Foreman Journal: J Immunol Date: 2013-09-27 Impact factor: 5.422
Authors: Courtney A Crane; Seunggu J Han; Jeffery J Barry; Brian J Ahn; Lewis L Lanier; Andrew T Parsa Journal: Neuro Oncol Date: 2009-11-05 Impact factor: 12.300
Authors: Jennifer C Rodrigues; Guido C Gonzalez; Lei Zhang; George Ibrahim; John J Kelly; Michael P Gustafson; Yi Lin; Allan B Dietz; Peter A Forsyth; V Wee Yong; Ian F Parney Journal: Neuro Oncol Date: 2009-12-22 Impact factor: 12.300
Authors: Christine E Brown; Darya Alizadeh; Renate Starr; Lihong Weng; Jamie R Wagner; Araceli Naranjo; Julie R Ostberg; M Suzette Blanchard; Julie Kilpatrick; Jennifer Simpson; Anita Kurien; Saul J Priceman; Xiuli Wang; Todd L Harshbarger; Massimo D'Apuzzo; Julie A Ressler; Michael C Jensen; Michael E Barish; Mike Chen; Jana Portnow; Stephen J Forman; Behnam Badie Journal: N Engl J Med Date: 2016-12-29 Impact factor: 91.245
Authors: Kara W Moyes; Nicole A P Lieberman; Shannon A Kreuser; Harrison Chinn; Conrad Winter; Gail Deutsch; Virginia Hoglund; Reid Watson; Courtney A Crane Journal: Hum Gene Ther Date: 2016-10-18 Impact factor: 5.695
Authors: Ashley S Plant; Shohei Koyama; Claire Sinai; Isaac H Solomon; Gabriel K Griffin; Keith L Ligon; Pratiti Bandopadhayay; Rebecca Betensky; Ryan Emerson; Glenn Dranoff; Mark W Kieran; Jerome Ritz Journal: J Neurooncol Date: 2018-01-10 Impact factor: 4.130
Authors: Karen C Wheeler; Manoj K Jena; Bhola S Pradhan; Neha Nayak; Subhendu Das; Chaur-Dong Hsu; David S Wheeler; Kang Chen; Nihar R Nayak Journal: PLoS One Date: 2018-01-11 Impact factor: 3.240
Authors: Nicole A P Lieberman; Kole DeGolier; Kristen Haberthur; Harrison Chinn; Kara W Moyes; Myriam N Bouchlaka; Kirsti L Walker; Christian M Capitini; Courtney A Crane Journal: Front Immunol Date: 2018-02-02 Impact factor: 7.561
Authors: James L Ross; Zhihong Chen; Cameron J Herting; Yura Grabovska; Frank Szulzewsky; Montserrat Puigdelloses; Lenore Monterroza; Jeffrey Switchenko; Nitin R Wadhwani; Patrick J Cimino; Alan Mackay; Chris Jones; Renee D Read; Tobey J MacDonald; Matthew Schniederjan; Oren J Becher; Dolores Hambardzumyan Journal: Brain Date: 2021-02-12 Impact factor: 13.501
Authors: Jessica B Foster; Peter J Madsen; Meenakshi Hegde; Nabil Ahmed; Kristina A Cole; John M Maris; Adam C Resnick; Phillip B Storm; Angela J Waanders Journal: Neuro Oncol Date: 2019-10-09 Impact factor: 12.300
Authors: Flor Mendez; Padma Kadiyala; Felipe J Nunez; Stephen Carney; Fernando M Nunez; Jessica C Gauss; Ramya Ravindran; Sheeba Pawar; Marta Edwards; Maria Belen Garcia-Fabiani; Santiago Haase; Pedro R Lowenstein; Maria G Castro Journal: Clin Cancer Res Date: 2020-04-24 Impact factor: 12.531
Authors: Rachael L Terry; Deborah Meyran; David S Ziegler; Michelle Haber; Paul G Ekert; Joseph A Trapani; Paul J Neeson Journal: J Clin Invest Date: 2020-07-01 Impact factor: 14.808